Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Correction to: 18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors.

Michaud L, Beattie BJ, Akhurst T, Dunphy M, Zanzonico P, Finn R, Mauguen A, Schöder H, Weber WA, Lassman AB, Blasberg R.

Eur J Nucl Med Mol Imaging. 2019 Sep 7. doi: 10.1007/s00259-019-04514-1. [Epub ahead of print]

PMID:
31492997
2.

18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors.

Michaud L, Beattie BJ, Akhurst T, Dunphy M, Zanzonico P, Finn R, Mauguen A, Schöder H, Weber WA, Lassman AB, Blasberg R.

Eur J Nucl Med Mol Imaging. 2019 Aug 15. doi: 10.1007/s00259-019-04433-1. [Epub ahead of print] Erratum in: Eur J Nucl Med Mol Imaging. 2019 Sep 7;:.

PMID:
31418054
3.

Testing Clonal Relatedness of Two Tumors from the Same Patient based on their Mutational Profiles: update of the Clonality R Package.

Mauguen A, Seshan VE, Begg CB, Ostrovnaya I.

Bioinformatics. 2019 Jun 14. pii: btz486. doi: 10.1093/bioinformatics/btz486. [Epub ahead of print]

PMID:
31198957
4.

Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.

Slotkin EK, Diolaiti D, Shukla NN, Dela Cruz FS, Clark JJ, Gundem G, Yellapantula VD, Levine MF, You D, Ma P, Pachhal S, Ibanez Sanchez G, Benayed R, Jungbluth AA, Smyth LM, Mauguen A, Gushterova I, Ding H, Spraggon L, Darnell R, Califano A, Ladanyi M, Papaemmanuil E, Kung AL, Hyman DM, Roberts SS.

Cancer Discov. 2019 May;9(5):605-616. doi: 10.1158/2159-8290.CD-18-0953. Epub 2019 Mar 15.

PMID:
30877085
5.

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.

Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA.

Haematologica. 2018 Sep;103(9):1577. doi: 10.3324/haematol.2018.199414. No abstract available.

6.

Total retinal detachments due to retinoblastoma: Outcomes following intra-arterial chemotherapy/ophthalmic artery chemosurgery.

Rowlands MA, Mondesire-Crump I, Levin A, Mauguen A, Francis JH, Dunkel IJ, Brodie SE, Gobin YP, Abramson DH.

PLoS One. 2018 Apr 26;13(4):e0195395. doi: 10.1371/journal.pone.0195395. eCollection 2018.

7.

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.

Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA.

Haematologica. 2018 May;103(5):770-777. doi: 10.3324/haematol.2017.187047. Epub 2018 Feb 1. Erratum in: Haematologica. 2018 Sep;103(9):1577.

8.

Contralateral breast cancers: Independent cancers or metastases?

Begg CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, Ng CKY, Sakr RA, Bernstein JL, Burke KA, King TA, Piscuoglio S, Mauguen A, Orlow I, Weigelt B, Seshan VE, Morrow M, Reis-Filho JS.

Int J Cancer. 2018 Jan 15;142(2):347-356. doi: 10.1002/ijc.31051. Epub 2017 Sep 28.

9.

Defining Cancer Subtypes With Distinctive Etiologic Profiles: An Application to the Epidemiology of Melanoma.

Mauguen A, Zabor EC, Thomas NE, Berwick M, Seshan VE, Begg CB.

J Am Stat Assoc. 2017;112(517):54-63. doi: 10.1080/01621459.2016.1191499. Epub 2017 May 3.

10.

Estimating the probability of clonal relatedness of pairs of tumors in cancer patients.

Mauguen A, Seshan VE, Ostrovnaya I, Begg CB.

Biometrics. 2018 Mar;74(1):321-330. doi: 10.1111/biom.12710. Epub 2017 May 8.

11.

Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events.

Mauguen A, Michiels S, Rondeau V.

J Biopharm Stat. 2017;27(6):1043-1053. doi: 10.1080/10543406.2017.1295249. Epub 2017 Mar 20.

PMID:
28319455
12.

Clonal relationships between lobular carcinoma in situ and other breast malignancies.

Begg CB, Ostrovnaya I, Carniello JV, Sakr RA, Giri D, Towers R, Schizas M, De Brot M, Andrade VP, Mauguen A, Seshan VE, King TA.

Breast Cancer Res. 2016 Jun 23;18(1):66. doi: 10.1186/s13058-016-0727-z.

13.

Using the Lorenz Curve to Characterize Risk Predictiveness and Etiologic Heterogeneity.

Mauguen A, Begg CB.

Epidemiology. 2016 Jul;27(4):531-7. doi: 10.1097/EDE.0000000000000499.

14.

Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study.

Lueza B, Mauguen A, Pignon JP, Rivero-Arias O, Bonastre J; MAR-LC Collaborative Group.

PLoS One. 2016 Mar 9;11(3):e0150032. doi: 10.1371/journal.pone.0150032. eCollection 2016.

15.

Dynamic prediction models for clustered and interval-censored outcomes: Investigating the intra-couple correlation in the risk of dementia.

Rondeau V, Mauguen A, Laurent A, Berr C, Helmer C.

Stat Methods Med Res. 2017 Oct;26(5):2168-2183. doi: 10.1177/0962280215594835. Epub 2015 Jul 15.

PMID:
26184832
16.

Time-varying coefficients in a multivariate frailty model: Application to breast cancer recurrences of several types and death.

Mazroui Y, Mauguen A, Mathoulin-Pélissier S, MacGrogan G, Brouste V, Rondeau V.

Lifetime Data Anal. 2016 Apr;22(2):191-215. doi: 10.1007/s10985-015-9327-y. Epub 2015 May 6.

PMID:
25944225
17.

Validation of death prediction after breast cancer relapses using joint models.

Mauguen A, Rachet B, Mathoulin-Pélissier S, Lawrence GM, Siesling S, MacGrogan G, Laurent A, Rondeau V.

BMC Med Res Methodol. 2015 Apr 1;15:27. doi: 10.1186/s12874-015-0018-x.

18.

Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients.

Ramaekers BL, Joore MA, Lueza B, Bonastre J, Mauguen A, Pignon JP, Le Pechoux C, De Ruysscher DK; MAR-LC Collaborative group, Grutters JP.

J Thorac Oncol. 2013 Oct;8(10):1295-307. doi: 10.1097/JTO.0b013e31829f6c55.

19.

Reply to 'interpretation of concordance measures for clustered data'.

Mauguen A, Collette S, Pignon JP, Rondeau V.

Stat Med. 2014 Feb 20;33(4):717-8. doi: 10.1002/sim.6022. No abstract available.

PMID:
24425542
20.

Auditory stimuli mimicking ambient sounds drive temporal "delta-brushes" in premature infants.

Chipaux M, Colonnese MT, Mauguen A, Fellous L, Mokhtari M, Lezcano O, Milh M, Dulac O, Chiron C, Khazipov R, Kaminska A.

PLoS One. 2013 Nov 11;8(11):e79028. doi: 10.1371/journal.pone.0079028. eCollection 2013.

21.

Dynamic prediction of risk of death using history of cancer recurrences in joint frailty models.

Mauguen A, Rachet B, Mathoulin-Pélissier S, MacGrogan G, Laurent A, Rondeau V.

Stat Med. 2013 Dec 30;32(30):5366-80. doi: 10.1002/sim.5980. Epub 2013 Sep 13.

PMID:
24030899
22.

Concordance measures in shared frailty models: application to clustered data in cancer prognosis.

Mauguen A, Collette S, Pignon JP, Rondeau V.

Stat Med. 2013 Nov 30;32(27):4803-20. doi: 10.1002/sim.5852. Epub 2013 Jun 3.

PMID:
23729305
23.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S; Surrogate Lung Project Collaborative Group.

Lancet Oncol. 2013 Jun;14(7):619-26. doi: 10.1016/S1470-2045(13)70158-X. Epub 2013 May 14.

24.

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.

Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP; meta-analysis of bevacizumab in advanced NSCLC collaborative group.

Ann Oncol. 2013 Jan;24(1):20-30. doi: 10.1093/annonc/mds590. Epub 2012 Nov 23. Review. Erratum in: Ann Oncol. 2013 Apr;24(4):1133.

PMID:
23180113
25.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

26.

Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.

Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, Sause WT, Ball D, Belani CP, Bonner JA, Zajusz A, Dahlberg SE, Nankivell M, Mandrekar SJ, Paulus R, Behrendt K, Koch R, Bishop JF, Dische S, Arriagada R, De Ruysscher D, Pignon JP.

J Clin Oncol. 2012 Aug 1;30(22):2788-97. doi: 10.1200/JCO.2012.41.6677. Epub 2012 Jul 2.

27.

Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP).

Kilday JP, Mitra B, Domerg C, Ward J, Andreiuolo F, Osteso-Ibanez T, Mauguen A, Varlet P, Le Deley MC, Lowe J, Ellison DW, Gilbertson RJ, Coyle B, Grill J, Grundy RG.

Clin Cancer Res. 2012 Apr 1;18(7):2001-11. doi: 10.1158/1078-0432.CCR-11-2489. Epub 2012 Feb 14.

28.

Variation in the peritoneal cancer index scores between surgeons and according to when they are determined (before or after cytoreductive surgery).

Elias D, Souadka A, Fayard F, Mauguen A, Dumont F, Honore C, Goere D.

Eur J Surg Oncol. 2012 Jun;38(6):503-8. doi: 10.1016/j.ejso.2012.01.001. Epub 2012 Jan 26.

PMID:
22281154
29.

Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer.

Andre F, Conforti R, Moeder CB, Mauguen A, Arnedos M, Berrada N, Delaloge S, Tomasic G, Spielmann M, Esteva FJ, Rimm DL, Michiels S.

Ann Oncol. 2012 Aug;23(8):2059-64. doi: 10.1093/annonc/mdr569. Epub 2012 Jan 11.

PMID:
22241898
30.

Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study.

Lamant L, McCarthy K, d'Amore E, Klapper W, Nakagawa A, Fraga M, Maldyk J, Simonitsch-Klupp I, Oschlies I, Delsol G, Mauguen A, Brugières L, Le Deley MC.

J Clin Oncol. 2011 Dec 10;29(35):4669-76. doi: 10.1200/JCO.2011.36.5411. Epub 2011 Nov 14.

PMID:
22084369
31.

Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).

Gauler TC, Besse B, Mauguen A, Meric JB, Gounant V, Fischer B, Overbeck TR, Krissel H, Laurent D, Tiainen M, Commo F, Soria JC, Eberhardt WE.

Ann Oncol. 2012 Mar;23(3):678-87. doi: 10.1093/annonc/mdr255. Epub 2011 May 26.

PMID:
21617019
32.

Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).

Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, Mauguen A, Barbu V, Coulet F, Prétet JL, Bièche I, Blons H, Boyer JC, Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier-Mirebeau D, Richard N, Danel C, Brambilla E, Chouaid C, Zalcman G, Hainaut P, Michiels S, Cadranel J.

J Thorac Oncol. 2011 Jun;6(6):1006-15. doi: 10.1097/JTO.0b013e318211dcee.

33.

[Survival and prognostic factors after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer].

Touboul C, Uzan C, Mauguen A, Gouy S, Rey A, Pautier P, Haie-Meder C, Morice P.

Gynecol Obstet Fertil. 2011 May;39(5):274-80. doi: 10.1016/j.gyobfe.2011.03.001. Epub 2011 Apr 15. French.

PMID:
21497541
34.

Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma.

Attarbaschi A, Mann G, Rosolen A, Williams D, Uyttebroeck A, Marky I, Lamant L, Horibe K, Wrobel G, Beishuizen A, Wössmann W, Reiter A, Mauguen A, Le Deley MC, Brugières L; European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) ALCL99 Trial.

Blood. 2011 May 26;117(21):5616-9. doi: 10.1182/blood-2010-12-324012. Epub 2011 Mar 28.

35.

Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.

Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, Billiot F, Mauguen A, Hill C, Escudier B.

Br J Cancer. 2011 Mar 29;104(7):1144-50. doi: 10.1038/bjc.2011.72. Epub 2011 Mar 8.

36.

Dose-finding approach for dose escalation with overdose control considering incomplete observations.

Mauguen A, Le Deley MC, Zohar S.

Stat Med. 2011 Jun 15;30(13):1584-94. doi: 10.1002/sim.4128. Epub 2011 Feb 24.

PMID:
21351289
37.

Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial.

Wrobel G, Mauguen A, Rosolen A, Reiter A, Williams D, Horibe K, Brugières L, Le Deley MC; European Inter-Group for Childhood, Non-Hodgkin Lymphoma (EICNHL).

Pediatr Blood Cancer. 2011 Jul 1;56(7):1071-7. doi: 10.1002/pbc.22940. Epub 2011 Jan 28.

PMID:
21280197
38.

[Postoperative morbidity after completion surgery following homogeneous chemoradiation therapy in locally advanced cervical cancer].

Touboul C, Uzan C, Mauguen A, Gouy S, Rey A, Pautier P, Lhommé C, Duvillard P, Haie-Meder C, Morice P.

J Gynecol Obstet Biol Reprod (Paris). 2010 Dec;39(8):624-31. doi: 10.1016/j.jgyn.2010.09.009. Epub 2010 Oct 27. French.

39.

Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis.

Peyre M, Commo F, Dantas-Barbosa C, Andreiuolo F, Puget S, Lacroix L, Drusch F, Scott V, Varlet P, Mauguen A, Dessen P, Lazar V, Vassal G, Grill J.

PLoS One. 2010 Sep 24;5(9):e12932. doi: 10.1371/journal.pone.0012932.

40.

Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial.

Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, Zsiros J, Uyttebroeck A, Marky IM, Lamant L, Woessmann W, Pillon M, Hobson R, Mauguen A, Reiter A, Brugières L.

J Clin Oncol. 2010 Sep 1;28(25):3987-93. doi: 10.1200/JCO.2010.28.5999. Epub 2010 Aug 2.

PMID:
20679620
41.

Neuronal differentiation distinguishes supratentorial and infratentorial childhood ependymomas.

Andreiuolo F, Puget S, Peyre M, Dantas-Barbosa C, Boddaert N, Philippe C, Mauguen A, Grill J, Varlet P.

Neuro Oncol. 2010 Nov;12(11):1126-34. doi: 10.1093/neuonc/noq074. Epub 2010 Jul 8.

42.

Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer.

Touboul C, Uzan C, Mauguen A, Gouy S, Rey A, Pautier P, Lhommé C, Duvillard P, Haie-Meder C, Morice P.

Oncologist. 2010;15(4):405-15. doi: 10.1634/theoncologist.2009-0295. Epub 2010 Mar 23.

43.

Coordinated expression of activated mitogen-activated protein kinases in salivary gland adenoid cystic carcinoma.

Handra-Luca A, Mauguen A, Ménard P, Fouret P.

Hum Pathol. 2008 Nov;39(11):1590-6. doi: 10.1016/j.humpath.2008.04.008. Epub 2008 Jul 26.

PMID:
18657296

Supplemental Content

Loading ...
Support Center